fashion -WSS

fashion

author：knowledge 2025-09-27 12:34:20 - browse：797

Exterior photo of UnitedHealth Group building — UnitedHealth Group is attempting to buy Amedisys for $3.3 billion. Courtesy UnitedHealth Group

There’s now a two-party showdown for one of the largest home health companies in the country.

UnitedHealth Group and its Optum division on Monday formally proposed to buy Amedisys for $100 per share, or about $3.3 billion.

The offer comes a few weeks after Option Care Health proposed a $3.6 billion takeover. However, Option Care’s deal is an all-stock transaction, whereas UnitedHealth would pay all cash — a potentially more attractive offer for Amedisys shareholders who want a more immediate payout that isn’t tied to the unpredictability of another company’s stock price. Option Care’s offer is technically worth closer to $2.8 billion now, due to the drop in Option Care’s stock price since the merger was announced. Amedisys is recommending shareholders vote in favor of the deal with Option Care.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

knowledge

WSS

Biotech reporter’s notebook: A sunnier mood at JPM 2024

Health and fitness trackers are measuring the wrong things

Liquid biopsy for lung cancer is launched by Delfi

As JPM 2024 winds down, some health tech firms project optimism

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

Health and fitness trackers are measuring the wrong things

explore

fashion

knowledge

Hepatitis C has a cure — but many Americans still lack access to it

3 questions for the future of Biden's cancer moonshot

Hepatitis C has a cure — but many Americans still lack access to it

Caregivers of transplant patients call for more support, training

Trump demands the U.S. pay no more for drugs than other countries … again

Designating disabled people as health disparity population is crucial

How to save PrEP access — and even expand it

Chan Zuckerberg Biohub Chicago to focus on inflammation

Walensky prepares to leave CDC — and Congress — behind

The nurse manager staffing crisis is hurting patients

hotspot

JPM 2024: Verve Therapeutics looks to mainstream genome editing

Sana to lay off nearly a third of staff, de

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

Phenylephrine and the overlooked value of the placebo effect

JPM 2024: Nvidia claims we're in biological revolution. Are we?

FDA panel signals lack of confidence in Amgen cancer drug data

knowledge

hotspot

hotspot

hotspot